{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:54:11Z","timestamp":1782996851043,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Basic Science Foundation of Shanxi Province","award":["202303021222340"],"award-info":[{"award-number":["202303021222340"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02484-9","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T02:04:06Z","timestamp":1744682646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrated bioinformatics analysis reveals that OPRK1 inhibits ferroptosis and induces enzalutamide resistance in prostate cancer"],"prefix":"10.1186","volume":"30","author":[{"given":"Liangrong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangkai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2484_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2484_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/cac2.12197","volume":"41","author":"H Qiu","year":"2021","unstructured":"Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41:1037\u201348.","journal-title":"Cancer Commun (Lond)"},{"key":"2484_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12935-024-03462-7","volume":"24","author":"M Wang","year":"2024","unstructured":"Wang M, Dai B, Liu Q, Zhang X. Prognostic and immunological implications of heterogeneous cell death patterns in prostate cancer. Cancer Cell Int. 2024;24:297.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"2484_CR4","first-page":"209","volume":"71","author":"Q Huang","year":"2024","unstructured":"Huang Q, Mitchell C, Theodoulou E, Lee ACK, Brown J. Implementation of fracture risk assessment in men with prostate cancer requiring long-term androgen deprivation therapy: a systematic scoping review using the i-PARIHS implementation framework. J Cancer Surviv. 2024;71(3):209.","journal-title":"J Cancer Surviv"},{"key":"2484_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102818","volume":"130","author":"E Akkus","year":"2024","unstructured":"Akkus E, Arslan \u00c7, \u00dcr\u00fcn Y. Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: insights and perspectives. Cancer Treat Rev. 2024;130: 102818.","journal-title":"Cancer Treat Rev"},{"key":"2484_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"2484_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40264-024-01415-7","volume":"47","author":"BW Lennep","year":"2024","unstructured":"Lennep BW, et al. Enzalutamide: understanding and managing drug interactions to improve patient safety and drug efficacy. Drug Saf. 2024;47:617\u201341.","journal-title":"Drug Saf"},{"key":"2484_CR8","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s40265-018-1029-9","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott LJ. Enzalutamide: a review in castration-resistant prostate cancer. Drugs. 2018;78:1913\u201324.","journal-title":"Drugs"},{"key":"2484_CR9","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.2147\/DDDT.S69433","volume":"9","author":"A Rodriguez-Vida","year":"2015","unstructured":"Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S, Sternberg CN. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2015;9:3325\u201339.","journal-title":"Drug Des Devel Ther"},{"key":"2484_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104273","volume":"196","author":"L Zhen","year":"2024","unstructured":"Zhen L, et al. A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: how to choose drugs appropriately? Crit Rev Oncol Hematol. 2024;196: 104273.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2484_CR11","doi-asserted-by":"publisher","first-page":"1006101","DOI":"10.3389\/fendo.2022.1006101","volume":"13","author":"AE Harris","year":"2022","unstructured":"Harris AE, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Front Endocrinol. 2022;13:1006101.","journal-title":"Front Endocrinol"},{"key":"2484_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217070","volume":"597","author":"HJ Chen","year":"2024","unstructured":"Chen HJ, et al. SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer. Cancer Lett. 2024;597: 217070.","journal-title":"Cancer Lett"},{"key":"2484_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41585-021-00470-4","volume":"18","author":"SD Lokeshwar","year":"2021","unstructured":"Lokeshwar SD, Klaassen Z, Saad F. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nat Rev Urol. 2021;18:433\u201342.","journal-title":"Nat Rev Urol"},{"key":"2484_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216725","volume":"587","author":"H Chen","year":"2024","unstructured":"Chen H, et al. CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression. Cancer Lett. 2024;587: 216725.","journal-title":"Cancer Lett"},{"issue":"2022","key":"2484_CR15","first-page":"10","volume":"14","author":"Z Zheng","year":"2022","unstructured":"Zheng Z, et al. The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer. Cancers. 2022;14(2022):10.","journal-title":"Cancers"},{"key":"2484_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41420-022-00951-4","volume":"8","author":"H Chen","year":"2022","unstructured":"Chen H, et al. Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65\/AR-V7. Cell Death Discov. 2022;8:241.","journal-title":"Cell Death Discov"},{"key":"2484_CR17","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019;129:4492\u2013505.","journal-title":"J Clin Invest"},{"key":"2484_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298\u2013305.","journal-title":"Nat Med"},{"key":"2484_CR19","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/ntr\/ntad118","volume":"25","author":"J Shao","year":"2023","unstructured":"Shao J, Fei Y, Xiao J, Wang L, Zou S, Yang J. The role of miRNA-144-3p\/Oprk1\/KOR in nicotine dependence and nicotine withdrawal in male rats. Nicotine Tob Res. 2023;25:1856\u201364.","journal-title":"Nicotine Tob Res"},{"key":"2484_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neulet.2015.08.027","volume":"606","author":"H Ji","year":"2015","unstructured":"Ji H, et al. OPRK1 promoter hypermethylation increases the risk of Alzheimer\u2019s disease. Neurosci Lett. 2015;606:24\u20139.","journal-title":"Neurosci Lett"},{"key":"2484_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12871-021-01429-z","volume":"21","author":"H Li","year":"2021","unstructured":"Li H, Ma Z, Lei Y. The expression of kappa-opioid receptor promotes the migration of breast cancer cells in vitro. BMC Anesthesiol. 2021;21:210.","journal-title":"BMC Anesthesiol"},{"key":"2484_CR22","doi-asserted-by":"publisher","first-page":"153303382110521","DOI":"10.1177\/15330338211052154","volume":"20","author":"L Wang","year":"2021","unstructured":"Wang L, Yao Y, Xu C, Wang X, Wu D, Hong Z. Exploration of the tumor mutational burden as a prognostic biomarker and related hub gene identification in prostate cancer. Technol Cancer Res Treat. 2021;20:15330338211052154.","journal-title":"Technol Cancer Res Treat"},{"key":"2484_CR23","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.2147\/IJGM.S434076","volume":"16","author":"S Wu","year":"2023","unstructured":"Wu S, Chen J, Huang E, Zhang Y. Pan-cancer analysis and validation of opioid-related receptors reveals the immunotherapeutic value of toll-like receptor 4. Int J Gen Med. 2023;16:5527\u201348.","journal-title":"Int J Gen Med"},{"key":"2484_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s42003-022-03227-w","volume":"5","author":"Y Makino","year":"2022","unstructured":"Makino Y, et al. Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1. Commun Biol. 2022;5:299.","journal-title":"Commun Biol"},{"key":"2484_CR25","first-page":"164","volume":"6","author":"H Yamashita","year":"2018","unstructured":"Yamashita H, Shuman L, Warrick JI, Raman JD, Degraff DJ. Androgen represses opioid growth factor receptor (OGFR) in human prostate cancer LNCaP cells and OGFR expression in human prostate cancer tissue. Am J Clin Exp Urol. 2018;6:164\u201371.","journal-title":"Am J Clin Exp Urol"},{"key":"2484_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112477","volume":"145","author":"Z Rezaei","year":"2022","unstructured":"Rezaei Z, et al. Identification of early diagnostic biomarkers via WGCNA in gastric cancer. Biomed Pharmacother. 2022;145: 112477.","journal-title":"Biomed Pharmacother"},{"key":"2484_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01442-y","author":"MR Wengler","year":"2025","unstructured":"Wengler MR, Talbot NJ. Mechanisms of regulated cell death during plant infection by the rice blast fungus Magnaporthe oryzae. Cell Death Differ. 2025. https:\/\/doi.org\/10.1038\/s41418-024-01442-y.","journal-title":"Cell Death Differ"},{"key":"2484_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103480","volume":"80","author":"B Puente-Cobacho","year":"2024","unstructured":"Puente-Cobacho B, et al. De novo lipogenesis protects dormant breast cancer cells from ferroptosis and promotes metastasis. Redox Biol. 2024;80: 103480.","journal-title":"Redox Biol"},{"key":"2484_CR29","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309\u201322.","journal-title":"Cell"},{"key":"2484_CR30","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ajpath.2014.04.010","volume":"184","author":"M Knuuttila","year":"2014","unstructured":"Knuuttila M, et al. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. Am J Pathol. 2014;184:2163\u201373.","journal-title":"Am J Pathol"},{"key":"2484_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aam7479","author":"L Li","year":"2017","unstructured":"Li L, et al. Androgen receptor inhibitor-induced \u2018\u201cBRCAness\u201d\u2019 and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017. https:\/\/doi.org\/10.1126\/scisignal.aam7479.","journal-title":"Sci Signal"},{"key":"2484_CR32","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1038\/s41467-021-25624-1","volume":"12","author":"S Taavitsainen","year":"2021","unstructured":"Taavitsainen S, et al. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat Commun. 2021;12:5307.","journal-title":"Nat Commun"},{"key":"2484_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100985","volume":"70","author":"J Wang","year":"2023","unstructured":"Wang J, et al. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. Drug Resist Updat. 2023;70:100985.","journal-title":"Drug Resist Updat"},{"key":"2484_CR34","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","volume":"83","author":"R Sun","year":"2023","unstructured":"Sun R, et al. Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis. Cancer Res. 2023;83:3192\u2013204.","journal-title":"Cancer Res"},{"key":"2484_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.freeradbiomed.2023.06.006","volume":"205","author":"J Nie","year":"2023","unstructured":"Nie J, Zhang P, Liang C, Yu Y, Wang X. ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer. Free Radic Biol Med. 2023;205:318\u201331.","journal-title":"Free Radic Biol Med"},{"key":"2484_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11255-022-03113-8","volume":"54","author":"H Chen","year":"2022","unstructured":"Chen H, et al. The modified prostate health index (PHI) outperforms PHI density in the detection of clinical prostate cancer within the PSA grey zone. Int Urol Nephrol. 2022;54:749\u201356.","journal-title":"Int Urol Nephrol"},{"key":"2484_CR37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nrurol.2009.125","volume":"6","author":"P Rajan","year":"2009","unstructured":"Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol. 2009;6:454\u201360.","journal-title":"Nat Rev Urol"},{"key":"2484_CR38","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","volume":"81","author":"L Gao","year":"2021","unstructured":"Gao L, et al. KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer. Cancer Res. 2021;81:1026\u201339.","journal-title":"Cancer Res"},{"key":"2484_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eururo.2013.08.011","volume":"66","author":"P Rajan","year":"2014","unstructured":"Rajan P, et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol. 2014;66:32\u20139.","journal-title":"Eur Urol"},{"key":"2484_CR40","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1200\/JCO.2016.70.7794","volume":"35","author":"P Rajan","year":"2017","unstructured":"Rajan P, et al. Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study. J Clin Oncol. 2017;35:3566\u201374.","journal-title":"J Clin Oncol"},{"key":"2484_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1755-8794-3-43","volume":"3","author":"TL Romanuik","year":"2010","unstructured":"Romanuik TL, Wang G, Morozova O, Delaney A, Marra MA, Sadar MD. LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med Genom. 2010;3:43.","journal-title":"BMC Med Genom"},{"key":"2484_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bja.2020.10.021","volume":"126","author":"G Montagna","year":"2021","unstructured":"Montagna G, et al. Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br J Anaesth. 2021;126:367\u201376.","journal-title":"Br J Anaesth"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02484-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T14:49:31Z","timestamp":1744728571000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02484-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2484"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02484-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the Ethics Committee of The First Hospital of Shanxi Medical University (NO. DWYJ-2023-094) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}